Literature DB >> 18056981

Interleukin-6 and cachexia in ApcMin/+ mice.

Kristen A Baltgalvis1, Franklin G Berger, Maria Marjorette O Pena, J Mark Davis, Stephanie J Muga, James A Carson.   

Abstract

The Apc(Min/+) mouse has a mutation in the Apc tumor suppressor gene and develops intestinal polyps, beginning at 4 wk of age. This mouse develops cachexia by 6 mo, characterized by significant loss of muscle and fat tissue. The purpose of the present study was to determine the role of circulating interleukin-6 (IL-6) and the polyp burden for the development of cachexia in Apc(Min/+) mice. At 26 wk of age, mice exhibiting severe cachectic symptoms had a 61% decrease in gastrocnemius muscle weight, complete loss of epididymal fat, a 10-fold increase in circulating IL-6 levels, and an 89% increase in intestinal polyps compared with mildly cachectic animals. Apc(Min/+)/IL-6(-/-) mice did not lose gastrocnemius muscle mass or epididymal fat pad mass while overall polyp number decreased by 32% compared with Apc(Min/+) mice. Plasmid-based IL-6 overexpression in Apc(Min/+)/IL-6(-/-) mice led to a decrease in gastrocnemius muscle mass and epididymal fat pad mass and increased intestinal polyp burden. IL-6 overexpression did not induce cachexia in non-tumor-bearing mice. These data demonstrate that IL-6 is necessary for the onset of adipose and skeletal muscle wasting in the Apc(Min/+) mouse and that circulating IL-6 can regulate Apc(Min/+) mouse tumor burden.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056981     DOI: 10.1152/ajpregu.00716.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  119 in total

1.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.

Authors:  Kyle R Bohnert; Praneeth Goli; Anirban Roy; Aditya K Sharma; Guangyan Xiong; Yann S Gallot; Ashok Kumar
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

Review 3.  Interleukin 6 as a key regulator of muscle mass during cachexia.

Authors:  James A Carson; Kristen A Baltgalvis
Journal:  Exerc Sport Sci Rev       Date:  2010-10       Impact factor: 6.230

4.  Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Authors:  Joshua R Huot; Leah J Novinger; Fabrizio Pin; Ashok Narasimhan; Teresa A Zimmers; Thomas M O'Connell; Andrea Bonetto
Journal:  JCI Insight       Date:  2020-05-07

5.  Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia.

Authors:  Maria Lima; Shuichi Sato; Reilly T Enos; John W Baynes; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2013-01-17

6.  Non-cell-autonomous stimulation of stem cell proliferation following ablation of Tcf3.

Authors:  Fei Yi; Bradley J Merrill
Journal:  Exp Cell Res       Date:  2009-12-16       Impact factor: 3.905

Review 7.  Roles for inflammation and regulatory T cells in colon cancer.

Authors:  Susan E Erdman; Theofilos Poutahidis
Journal:  Toxicol Pathol       Date:  2009-12-17       Impact factor: 1.902

8.  Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.

Authors:  James P White; Melissa J Puppa; Song Gao; Shuichi Sato; Stephen L Welle; James A Carson
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-26       Impact factor: 4.310

9.  Eccentric contraction-induced myofiber growth in tumor-bearing mice.

Authors:  Justin P Hardee; Joshua E Mangum; Song Gao; Shuichi Sato; Kimbell L Hetzler; Melissa J Puppa; Dennis K Fix; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2015-10-22

Review 10.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.